---
layout: default
title: Bevacizumab
description: "Bevacizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 33
evidence_level: L1
indication_count: 10
---

# Bevacizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Bevacizumabï¼šå¾å¤šç¨®ç™Œç—‡åˆ°æœƒå­è…«ç˜¤

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Bevacizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Bevacizumab åŸç‚ºæŠ—è¡€ç®¡æ–°ç”Ÿçš„ç™Œç—‡æ¨™é¶è—¥ç‰©ï¼Œç”¨æ–¼è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€è‚ºç™Œã€åµå·¢ç™Œç­‰å¤šç¨®æƒ¡æ€§è…«ç˜¤ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æœƒå­è…«ç˜¤(epiglottis neoplasm)æœ‰æ²»ç™‚æ½›åŠ›ã€‚
</p>

## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€ä¹³ç™Œã€éå°ç´°èƒè‚ºç™Œã€åµå·¢ç™Œã€å­å®®é ¸ç™Œã€ç¥ç¶“è† æ¯ç´°èƒç˜¤ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | epiglottis neoplasmã€benign neoplasm of tongueã€tumor of testis and paratestisã€benign neoplasm of hypopharynxã€benign neoplasm of floor of mouthã€cervical neuroblastomaã€cystic neoplasmã€nasal cavity inverting papillomaã€mesenchymomaã€schwannoma of jugular foramen |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ (Avastinã€MVASIã€ABEVMYã€Vegzelmaç­‰) |
| å»ºè­°æ±ºç­– | Explore |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. epiglottis neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Bevacizumab æ˜¯ä¸€ç¨®äººæºåŒ–å–®æ ªæŠ—é«”ï¼Œé€éçµåˆè¡€ç®¡å…§çš®ç”Ÿé•·å› å­(VEGF)ä¾†æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€‚å…¶ä½œç”¨æ©Ÿè½‰å…·æœ‰å»£æ³›çš„æŠ—è…«ç˜¤æ´»æ€§ï¼š</p>

<ol>
<li><strong>è¡€ç®¡æ–°ç”ŸæŠ‘åˆ¶</strong>ï¼šé˜»æ–· VEGF è¨Šè™Ÿå‚³å°ï¼Œæ¸›å°‘è…«ç˜¤è¡€ç®¡å½¢æˆ</li>
<li><strong>é ­é ¸éƒ¨ç™Œç—‡ç¶“é©—</strong>ï¼šå·²æ ¸å‡†ç”¨æ–¼é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œ(HNSCC)çš„æ²»ç™‚</li>
<li><strong>è§£å‰–ä½ç½®ç›¸é—œ</strong>ï¼šæœƒå­å±¬æ–¼é ­é ¸éƒ¨å€åŸŸï¼Œèˆ‡å·²æ ¸å‡†é©æ‡‰ç—‡çš„é ­é ¸éƒ¨ç™Œç—‡æœ‰ç›¸ä¼¼çš„è¡€ç®¡ç”Ÿæˆç‰¹æ€§</li>

</ol>
<p>æœƒå­è…«ç˜¤é›–ç‚ºç½•è¦‹ç–¾ç—…ï¼Œä½†å…¶è¡€ç®¡ä¾›æ‡‰ç‰¹æ€§èˆ‡å…¶ä»–é ­é ¸éƒ¨è…«ç˜¤ç›¸ä¼¼ï¼Œç†è«–ä¸Šå¯èƒ½å°æŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚æœ‰åæ‡‰ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å° bevacizumab æ²»ç™‚æœƒå­è…«ç˜¤çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<p>ç„¶è€Œï¼Œç›¸é—œçš„é ­é ¸éƒ¨ç™Œç—‡è‡¨åºŠè©¦é©—åŒ…æ‹¬ï¼š</p>
<ul>
<li><strong>NCT01552434</strong>ï¼šPhase I è©¦é©—ï¼Œè©•ä¼° bevacizumab èˆ‡ temsirolimus åœ¨æ™šæœŸæƒ¡æ€§è…«ç˜¤çš„æ‡‰ç”¨</li>
<li><strong>NCT00023959</strong>ï¼šPhase I è©¦é©—ï¼Œè©•ä¼° bevacizumab åˆä½µåŒ–æ”¾ç™‚æ²»ç™‚é å¾Œä¸è‰¯çš„é ­é ¸éƒ¨ç™Œç—‡</li>
</ul>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>PubMed æª¢ç´¢ç™¼ç¾æœ‰é—œæ–¼ bevacizumab åœ¨é ­é ¸éƒ¨ç™Œç—‡çš„è‡¨åºŠå‰ç ”ç©¶ï¼š</p>

<ul>
<li>Bozec A ç­‰äºº(2008)ç™¼è¡¨æ–¼ *British Journal of Cancer*ï¼Œè­‰å¯¦ bevacizumab åˆä½µ erlotinib åŠæ”¾ç™‚åœ¨é ­é ¸éƒ¨è…«ç˜¤æ­£ä½æ¨¡å¼ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœ</li>
<li>å¤šç¯‡ç ”ç©¶æ”¯æŒæŠ— VEGF ç™‚æ³•åœ¨é ­é ¸éƒ¨è…«ç˜¤çš„æ‡‰ç”¨æ½›åŠ›</li>
</ul>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. benign neoplasm of tongue</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ7 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39927612/" target="_blank">39927612</a></td><td>2025</td><td>Article</td><td>Expert opinion on ph</td><td>Oral mucosal toxicities in oncology.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16496361/" target="_blank">16496361</a></td><td>2006</td><td>Article</td><td>Journal of surgical </td><td>Re: Correlational of oral tongue cancer inversion with matri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20187015/" target="_blank">20187015</a></td><td>2010</td><td>Article</td><td>Head &amp; neck</td><td>Chemoradiotherapy for locoregionally advanced squamous cell ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40418990/" target="_blank">40418990</a></td><td>2025</td><td>Article</td><td>Journal of controlle</td><td>Multi-modality imaging for precise intra-arterial delivery o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21236594/" target="_blank">21236594</a></td><td>2012</td><td>Article</td><td>International journa</td><td>Tumor metabolism and perfusion in head and neck squamous cel...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 2 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. tumor of testis and paratestis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. benign neoplasm of hypopharynx</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. benign neoplasm of floor of mouth</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01552434" target="_blank">NCT01552434</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>155</td><td>A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valpr...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18577994/" target="_blank">18577994</a></td><td>2008</td><td>Article</td><td>British journal of c</td><td>Combined effects of bevacizumab with erlotinib and irradiati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21862388/" target="_blank">21862388</a></td><td>2011</td><td>Article</td><td>Oral oncology</td><td>Antitumor activity of cetuximab associated with the taxotere...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. cervical neuroblastoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ5 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00101348" target="_blank">NCT00101348</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>66</td><td>A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00492089" target="_blank">NCT00492089</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01096381" target="_blank">NCT01096381</a></td><td>N/A</td><td>TERMINATED</td><td>8</td><td>A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06047379" target="_blank">NCT06047379</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>134</td><td>An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00023959" target="_blank">NCT00023959</a></td><td>PHASE1</td><td>COMPLETED</td><td>39</td><td>A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vas...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39446377/" target="_blank">39446377</a></td><td>2024</td><td>Article</td><td>JAMA oncology</td><td>Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22826790/" target="_blank">22826790</a></td><td>2012</td><td>Article</td><td>Rare tumors</td><td>Unexpectedly durable palliation of metastatic olfactory neur...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cystic neoplasm</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ8 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00101348" target="_blank">NCT00101348</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>66</td><td>A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00492089" target="_blank">NCT00492089</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00565851" target="_blank">NCT00565851</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>1052</td><td>A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01096381" target="_blank">NCT01096381</a></td><td>N/A</td><td>TERMINATED</td><td>8</td><td>A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03074513" target="_blank">NCT03074513</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>133</td><td>A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and B...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 3 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40644648/" target="_blank">40644648</a></td><td>2025</td><td>Article</td><td>Journal of clinical </td><td>Efficacy and Safety of Avutometinib Â± Defactinib in Recurren...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38328890/" target="_blank">38328890</a></td><td>2024</td><td>Article</td><td>Future oncology (Lon</td><td>Efficacy and safety of bevacizumab in patients with low-grad...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37657955/" target="_blank">37657955</a></td><td>2023</td><td>Article</td><td>Clinical colorectal </td><td>Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27412268/" target="_blank">27412268</a></td><td>2016</td><td>Article</td><td>Cancer</td><td>Weekly paclitaxel, capecitabine, and bevacizumab with mainte...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18796376/" target="_blank">18796376</a></td><td>2008</td><td>Article</td><td>Clinical &amp; translati</td><td>Combined oral cyclophosphamide and bevacizumab in heavily pr...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. nasal cavity inverting papilloma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00101348" target="_blank">NCT00101348</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>66</td><td>A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00492089" target="_blank">NCT00492089</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01096381" target="_blank">NCT01096381</a></td><td>N/A</td><td>TERMINATED</td><td>8</td><td>A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00023959" target="_blank">NCT00023959</a></td><td>PHASE1</td><td>COMPLETED</td><td>39</td><td>A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vas...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. mesenchymoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. schwannoma of jugular foramen</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
Bevacizumab åœ¨å°ç£æœ‰å¤šé …è—¥å“è¨±å¯è­‰ï¼š
- **Avastin (ç™Œæ€åœ)** - ç¾…æ°
- **MVASI** - å®‰é€²
- **ABEVMY** - ä¸‰æ˜Ÿç”ŸæŠ€
- **Vegzelma (è‰¾æ³•æ–½)** - ä¿¡æ±

æ ¸å‡†é©æ‡‰ç—‡æ¶µè“‹ï¼š
- è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œ
- è½‰ç§»æ€§ä¹³ç™Œ(HER2 é™°æ€§)
- éå°ç´°èƒè‚ºç™Œ
- ç¥ç¶“è† æ¯ç´°èƒç˜¤
- åµå·¢ä¸Šçš®ç´°èƒç™Œ
- å­å®®é ¸ç™Œ

## å®‰å…¨æ€§è€ƒé‡
### å¸¸è¦‹å‰¯ä½œç”¨
- é«˜è¡€å£“
- è›‹ç™½å°¿
- å‡ºè¡€äº‹ä»¶
- å‚·å£ç™’åˆå»¶é²

### åš´é‡è­¦èª
- èƒƒè…¸é“ç©¿å­”é¢¨éšª
- å‹•è„ˆè¡€æ “æ “å¡äº‹ä»¶
- éœ€ç›£æ¸¬è¡€å£“åŠè›‹ç™½å°¿

### è—¥ç‰©äº¤äº’ä½œç”¨
èˆ‡å…¶ä»–æŠ—ç™Œè—¥ç‰©ä½µç”¨æ™‚éœ€æ³¨æ„éª¨é«“æŠ‘åˆ¶åŠ æˆæ•ˆæ‡‰ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Hemorrhage** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**é«˜è¡€å£“** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Posterior Leukoencephalopathy Syndrome** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Proteinuria** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thromboembolism** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Fistula** ğŸŸ¢ Minor
- å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Peptic Ulcer Perforation** ğŸŸ¢ Minor
- å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**è­‰æ“šç­‰ç´š**ï¼šL5 (åƒ… TxGNN é æ¸¬ï¼Œç„¡è‡¨åºŠè­‰æ“š)

**å»ºè­°**ï¼š
1. æœƒå­è…«ç˜¤ç‚ºç½•è¦‹ç–¾ç—…ï¼Œç›®å‰ç„¡æ¨™æº–æ²»ç™‚æ–¹æ¡ˆæ™‚å¯è€ƒæ…®æ¢ç´¢æ€§ä½¿ç”¨
2. å»ºè­°å„ªå…ˆåƒè€ƒé ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œçš„ bevacizumab ä½¿ç”¨ç¶“é©—
3. è‹¥è€ƒæ…®è‡¨åºŠæ‡‰ç”¨ï¼Œæ‡‰åœ¨è…«ç˜¤å°ˆç§‘é†«å¸«æŒ‡å°ä¸‹é€²è¡Œ

**ä¸‹ä¸€æ­¥ç ”ç©¶æ–¹å‘**ï¼š
- å›é¡§æ€§åˆ†æé ­é ¸éƒ¨ç™Œç—‡ç—…ä¾‹ä¸­æœƒå­å—ç´¯çš„æ²»ç™‚åæ‡‰
- è€ƒæ…®å€‹æ¡ˆå ±å‘Šæˆ–å°è¦æ¨¡è‡¨åºŠè©¦é©—è©•ä¼°å¯è¡Œæ€§

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Voriconazole]({{ "/drugs/voriconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Disopyramide]({{ "/drugs/disopyramide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trifluoperazine]({{ "/drugs/trifluoperazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Povidone]({{ "/drugs/povidone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Bevacizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/bevacizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_bevacizumab,
  title = {Bevacizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/bevacizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
